DB06109ExperimentalSmall molecule
YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. In addition, the... In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
- Mechanism
- Curator reviewed
serotonin (5-HT2A) and dopamine (D2) antagonist.
- Primary indication
- Investigated for use/treatment in schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- YKP-1358
Resolves to
Targets
What you can answer from here — as of April 02, 2025
Which drugs share a target with YKP-1358, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account